The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Unmet needs in Hodgkin lymphoma
Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, comments on the improving cure rates for patients with Hodgkin lymphoma, highlighting the need for improved treatment regimens for older patients and the potential role of brentuximab vedotin and PD-1 inhibitors, as well as the need to improve the balance between efficacy and toxicity. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
